Candriam S.C.A. Terns Pharmaceuticals, Inc. Transaction History
Candriam S.C.A.
- $15.6 Billion
- Q1 2025
A detailed history of Candriam S.C.A. transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 2,153,969 shares of TERN stock, worth $7.67 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
2,153,969
Previous 2,153,969
-0.0%
Holding current value
$7.67 Million
Previous $12 Million
50.54%
% of portfolio
0.04%
Previous 0.07%
Shares
1 transactions
Others Institutions Holding TERN
# of Institutions
143Shares Held
84.5MCall Options Held
256KPut Options Held
133K-
Soleus Capital Management, L.P. Greenwich, CT8.17MShares$29.1 Million1.87% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.56MShares$26.9 Million0.65% of portfolio
-
Morgan Stanley New York, NY7.11MShares$25.3 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$24.5 Million5.17% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.58MShares$19.9 Million0.54% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $134M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...